Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

RegMed Daily, Mid-Day, 11/16/11, post-mortems on GERN impact continue to unfold

 The 6 W’s: Who, what, where, when, why and what of it …

 

Stocks moved lower at the start of trading on Wednesday, giving … back and forth … after moving mostly higher, yesterday. The major averages all moved to the downside but did not see much follow-through on the initial downward move. The major averages have climbed off their lows for the young session but currently remain negative.

 

Mid-Day: The NASDAQ is DOWN -2.43 (-0.09%) to 2,683.77. The Dow is DOWN -38.56 (-0.32%) to 12,057.60.

 

Mid-Day Movers: BioTime (AMEX: BTx), Dendreon (NASDAQ:DNDN), International Stem Cell (OTC BB; ISCO), ReNeuron (RENE.LON) and Tengion (TNGN).

 

What’s new in the regenerative medicine/stem cell market …

Aldagen Announces Publication of Mechanism of Action Data for Its Cardiovascular Cell Therapy Products: Publication in Journal of Stem Cell Research & Therapy Supports the Potential of Aldagen’s Cellular Therapies to Improve Blood Flow in Ischemic Tissues.  The paper, entitled Mechanisms of Action of Human Aldehyde Dehydrogenase Bright Cells in Therapy of Cardiovascular Diseases:Expression Analysis of Angiogenic Factors and Aldehyde Dehydrogenase Isozymes, describes the multiple mechanisms by which Aldagen’s cell therapy products promote formation of new blood vessels in ischemic tissues. These mechanisms include the expression of angiogenic genes encoding soluble growth factors, regulatory molecules and extracellular molecules that protect endothelial tubules from damage from hypoxia.

Stem Cell Scientist Discusses New Drug Development Process: Pharmaceutical companies should turn to stem cells for a more effective and cost-efficient way to experiment with new medications, Harvard professor Lee L. Rubin said in a presentation yesterday. Rubin, who is the Stem Cell and Regenerative Biology professor and a director at the Harvard Stem Cell Institute, said that because stem cells mimic the biological environment of the human body, they are an effective precursor to the long and pricey clinical trial phase. http://www.thecrimson.com/article/2011/11/16/big-pharma-talk

Fate Therapeutics strengthens its iPSC Platform: The (USPTO) United States Patent and Trademark Office has granted Fate Therapeutics a patent covering the novel stem cell modulator commonly known as Thiazovivin.  US Patent No# 8,044,201 entitled “Stem Cell Cultures” claims Thiazovivin, a small molecule Rho-associated kinase (NASDAQ:ROCK) inhibitor, as well as compositions and cell culture media comprising Thiazovivin. http://www.scimitarequity.com/blog/2011/11/16/fate-therapeutics-strengthens-its-ipsc-patent-platform/

California Institute of Regenerative Medicine (CIRM) Excerpts about Geron’s Decision:  Q&A about Geron’s decision and its implications for the stem cell field. http://www.scimitarequity.com/blog/2011/11/16/california-institute-of-regenerative-medicine-cirm-excerpts-about-geron%e2%80%99s-decision/